RESEARCH-USE BIOSIMILAR ANTIBODY
Ecleralimab
Antibody fragment · IgG1
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma.
TARGETTSLP
YAntibody fragment
CATALOGSC-BS-595
CATALOG NUMBERSC-BS-595
MOLECULAR WEIGHTApprox. 46.62 kDa
PRODUCT FORMATAntibody fragment
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma.
Ecleralimab is a recombinant research-use antibody directed against TSLP.